Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 2/20 | 0.54 |
| ▸ | PGR | P06401 | 2/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.36 |
| ▸ | IDH1 | O75874 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.36 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.35 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.35 |
| ▸ | TDP2 | O95551 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4789903 | 0.81 | ADRA2A (0.41) | HTR2CHRH1TDP2 | |
| SCHEMBL4790395 | 0.80 | SIGMAR1 (0.50) | HTR2CSLC6A3 | |
| SCHEMBL11016650 | 0.78 | NCOA1 (0.43) | HTR2CSLC6A3 | |
| SCHEMBL5120102 | 0.77 | HTR2C (0.57) | HTR2CHRH1SCN2APARP10PARP11 | |
| SCHEMBL9531972 | 0.74 | HTR2C (0.44) | HTR2CHRH1 | |
| SCHEMBL7747172 | 0.72 | QDPR (0.53) | — | |
| SCHEMBL5120309 | 0.71 | CYP11B1 (0.48) | — | |
| SCHEMBL4790016 | 0.70 | CYP2A6 (0.35) | — | |
| SCHEMBL4510248 | 0.70 | HTR2C (1.00) | HTR2C | |
| SCHEMBL4789908 | 0.69 | PTGS1 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008015271-A1 | PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THE USE AS A MEDICINE | MERZ PHARMA GMBH & CO. KGAA (DE) | 2008-02-07 | — | — | WO | disclosed |
| US-20080032998-A1 | Pyrazolopyrimidines, a process for their preparation and their use as medicine | MERZ PHARMA GMBH & CO. KGAA (DE) | 2008-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080032998-A1 | Pyrazolopyrimidines, a process for their preparation and their use as medicine | GRM5, GRM1, GRIK5 | HTR2C 222/4885PGR 781/4885HRH1 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.